novavax
host
conference
call
discuss
third
quarter
financial
operating
results
november
gaithersburg
globe
newswire
novavax
nasdaq
nvax
late
stage
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
report
third
quarter
financial
operating
results
following
close
financial
markets
monday
november
conference
call
details
follows
date
november
time
eastern
time
et
number
domestic
international
passcode
webcast
investors
events
conference
call
webcast
replay
dates
starting
et
november
et
november
number
domestic
international
passcode
webcast
investors
events
february
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
currently
conducting
multiple
clinical
trials
vaccine
candidate
virus
causes
including
pivotal
phase
clinical
trial
united
kingdom
evaluate
efficacy
safety
immunogenicity
individuals
aged
years
age
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
candidate
vaccines
incorporate
novavax
proprietary
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
contacts
investors
erika
trahan
ir
